Sfoglia per RIVISTA
CLINICAL LUNG CANCER
Collezione AOU San Luigi di Orbassano
Items : 20
Clinical-Molecular Prospective Cohort Study in Non-Small Cell Lung Cancer (PROMOLE study): A Comprehensive Approach to Identify New Predictive Markers of Pharmacological Response. in Clinical lung cancer / Clin Lung Cancer. 2022 Sep;23(6):e347-e352. doi: 10.1016/j.cllc.2022.05.007. Epub 2022 May 11.
2022
ASL Torino 4
AOU San Luigi di Orbassano
Pirri F; Bussolino F; Manganaro L; Candeloro S; Righi L; Novello S; Primo L; Bironzo P; Scagliotti GV;
PECATI: A Multicentric, Open-Label, Single-Arm Phase II Study to Evaluate the Efficacy and Safety of Pembrolizumab and Lenvatinib in Pretreated B3-Thymoma and Thymic Carcinoma Patients. in Clinical lung cancer / Clin Lung Cancer. 2022 May;23(3):e243-e246. doi: 10.1016/j.cllc.2021.07.008. Epub 2021 Jul 20.
2022
ASL Torino 4
AOU San Luigi di Orbassano
Besse B; Juan O; Mosquera J; Cousin S; Sampayo M; Greillier L; Bernabé R; de Castro J; Bigay-Game L; Novello S; Girard N; Remon J;
A Prospective Phase II Single-arm Study of Niraparib Plus Dostarlimab in Patients With Advanced Non-small-cell Lung Cancer and/or Malignant Pleural Mesothelioma, Positive for PD-L1 Expression and Germline or Somatic Mutations in the DNA Repair Genes: Rationale and Study Design. in Clinical lung cancer / Clin Lung Cancer. 2021 Jan;22(1):e63-e66. doi: 10.1016/j.cllc.2020.07.014. Epub 2020 Aug 5.
2021
AOU San Luigi di Orbassano
Scagliotti GV; Volante M; Novello S; Arizio F; Listì A; Righi L; Passiglia F; Bironzo P;
Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 Expression ? 50% and Their Relationship With Clinical Outcomes. in Clinical lung cancer / Clin Lung Cancer. 2020 Nov;21(6):498-508.e2. doi: 10.1016/j.cllc.2020.06.010. Epub 2020 Jun 21.
2020
AOU San Luigi di Orbassano
Belderbos RA; De Filippis M; Dal Bello MG; Della Gravara L; Bertolini F; Baldessari C; Guaitoli G; Landi L; Antonuzzo L; Scodes S; Pettoruti L; Leonetti A; D'Argento E; Ferrara MG; Nigro O; Sforza V; Follador A; Torniai M; Cantini L; Russano M; Citarella F; Occhipinti MA; Sala L; Pizzutilo P; Catino A; Filetti M; Ghidini M; Tudini M; Santoni M; et alii...
Update on International Cooperative Groups Studies in Thoracic Malignancies: The Emergence of Immunotherapy. in Clinical lung cancer / Clin Lung Cancer. 2018 Sep;19(5):377-386. doi: 10.1016/j.cllc.2018.03.004. Epub 2018 Mar 17.
2018
AOU San Luigi di Orbassano
Shukla ND; Salahudeen AA; Taylor GA; Ramalingam SS; Vokes EE; Goss GD; Decker RH; Kelly K; Scagliotti GV; Mok TS; Wakelee HA;
Effect of Contract Research Organization Bureaucracy in Clinical Trial Management: A Model From Lung Cancer. in Clinical lung cancer / Clin Lung Cancer. 2018 Mar;19(2):191-198. doi: 10.1016/j.cllc.2017.10.012. Epub 2017 Oct 28.
2018
AOU San Luigi di Orbassano
Gobbini E; Pilotto S; Pasello G; Polo V; Di Maio M; Arizio F; Galetta D; Petrillo P; Chiari R; Matocci R; Di Costanzo A; Di Stefano TS; Aglietta M; Cagnazzo C; Sperduti I; Bria E; Novello S;
The APPLE Trial: Feasibility and Activity of AZD9291 (Osimertinib) Treatment on Positive PLasma T790M in EGFR-mutant NSCLC Patients. EORTC 1613. in Clinical lung cancer / Clin Lung Cancer. 2017 Sep;18(5):583-588. doi: 10.1016/j.cllc.2017.02.005. Epub 2017 Mar 1.
2017
AOU San Luigi di Orbassano
Remon J; Menis J; Hasan B; Peric A; De Maio E; Novello S; Reck M; Berghmans T; Wasag B; Besse B; Dziadziuszko R;
Intercalated Chemotherapy and Epidermal Growth Factor Receptor Inhibitors for Patients With Advanced Non-Small-cell Lung Cancer: A Systematic Review and Meta-analysis. in Clinical lung cancer / Clin Lung Cancer. 2017 Jan;18(1):23-33.e1. doi: 10.1016/j.cllc.2016.08.006. Epub 2016 Oct 28.
2017
AOU San Luigi di Orbassano
La Salvia A; Rossi A; Galetta D; Gobbini E; De Luca E; Novello S; Di Maio M;
Efficacy and Safety of Onartuzumab in Combination With First-Line Bevacizumab- or Pemetrexed-Based Chemotherapy Regimens in Advanced Non-Squamous Non-Small-Cell Lung Cancer. in Clinical lung cancer / Clin Lung Cancer. 2017 Jan;18(1):50-59. doi: 10.1016/j.cllc.2016.09.013. Epub 2016 Oct 19.
2017
AOU San Luigi di Orbassano
Wakelee H; Zvirbule Z; De Braud F; Kingsley CD; Mekhail T; Lowe T; Schütte W; Lena H; Lawler W; Braiteh F; Cosgriff T; Kaen D; Boyer M; Hsu J; Phan S; Novello S;
Management of Italian patients with advanced non-small-cell lung cancer after second-line treatment: results of the longitudinal phase of the LIFE observational study. in Clinical lung cancer / Clin Lung Cancer. 2014 Sep;15(5):338-45.e1. doi: 10.1016/j.cllc.2014.04.004. Epub 2014 May 14.
2014
AOU San Luigi di Orbassano
de Marinis F; Ardizzoni A; Fontanini G; Grossi F; Cappuzzo F; Novello S; Santo A; Lorusso V; Cortinovis D; Iurlaro M; Galetta D; Gridelli C;
Early response to chemotherapy in patients with non-small-cell lung cancer assessed by [18F]-fluoro-deoxy-D-glucose positron emission tomography and computed tomography. in Clinical lung cancer / Clin Lung Cancer. 2013 May;14(3):230-7. doi: 10.1016/j.cllc.2012.10.004. Epub 2012 Dec 29.
2013
AOU San Luigi di Orbassano
Novello S; Vavalà T; Levra MG; Solitro F; Pelosi E; Veltri A; Scagliotti GV;
Clinical implications and added costs of incidental findings in an early detection study of lung cancer by using low-dose spiral computed tomography. in Clinical lung cancer / Clin Lung Cancer. 2013 Mar;14(2):139-48. doi: 10.1016/j.cllc.2012.05.005. Epub 2012 Aug 4.
2013
AOU San Luigi di Orbassano
Priola AM; Priola SM; Giaj-Levra M; Basso E; Veltri A; Fava C; Cardinale L;
Rationale and design of MARQUEE: a phase III, randomized, double-blind study of tivantinib plus erlotinib versus placebo plus erlotinib in previously treated patients with locally advanced or metastatic, nonsquamous, non-small-cell lung cancer. in Clinical lung cancer / Clin Lung Cancer. 2012 Sep;13(5):391-5. doi: 10.1016/j.cllc.2012.01.003. Epub 2012 Mar 21.
2012
AOU San Luigi di Orbassano
Scagliotti GV; Novello S; Schiller JH; Hirsh V; Sequist LV; Soria JC; von Pawel J; Schwartz B; Von Roemeling R; Sandler AB;
Primary pleuropulmonary sarcoma: a rare disease entity. in Clinical lung cancer / Clin Lung Cancer. 2012 Nov;13(6):399-407. doi: 10.1016/j.cllc.2012.05.003. Epub 2012 Jun 5.
2012
AOU San Luigi di Orbassano
Giaj Levra M; Novello S; Scagliotti GV; Papotti M; Le Cesne A;
Role of hormone receptor expression in patients with advanced-stage lung cancer treated with chemotherapy. in Clinical lung cancer / Clin Lung Cancer. 2012 Nov;13(6):416-23. doi: 10.1016/j.cllc.2012.03.006. Epub 2012 Jun 2.
2012
AOU San Luigi di Orbassano
Monica V; Longo M; Felice B; Scagliotti GV; Papotti M; Novello S;
New data integrating multitargeted antifolates into treatment of first-line and relapsed non-small-cell lung cancer. in Clinical lung cancer / Clin Lung Cancer. 2008;9 Suppl 3:S122-8. doi: 10.3816/CLC.2008.s.018.
2008
AOU San Luigi di Orbassano
Scagliotti GV; Selvaggi G;
Reactive thrombocytosis might contribute to chemotherapy-related thrombophilia in patients with lung cancer. in Clinical lung cancer / Clin Lung Cancer. 2007 Jan;8(4):264-7. doi: 10.3816/CLC.2007.n.004.
2007
AOU San Luigi di Orbassano
Zecchina G; Ghio P; Bosio S; Cravino M; Camaschella C; Scagliotti GV;
The way forward: new drugs and new therapeutic strategies in lung cancer therapy. in Clinical lung cancer / Clin Lung Cancer. 2006 May;7 Suppl 4:S109-10. doi: 10.3816/clc.2006.s.001.
2006
AOU San Luigi di Orbassano
Scagliotti GV; Novello S;
Prognostic role of protease-activated receptors 1 and 4 in resected stage IB non-small-cell lung cancer. in Clinical lung cancer / Clin Lung Cancer. 2006 May;7(6):395-400. doi: 10.3816/CLC.2006.n.023.
2006
AOU San Luigi di Orbassano
Ghio P; Cappia S; Selvaggi G; Novello S; Lausi P; Zecchina G; Papotti M; Borasio P; Scagliotti GV;
Current development of adjuvant treatment of non-small-cell lung cancer. in Clinical lung cancer / Clin Lung Cancer. 2004 Dec;6 Suppl 2:S63-70. doi: 10.3816/clc.2004.s.016.
2004
AOU San Luigi di Orbassano
Scagliotti GV; Novello S;